Definition/General

Introduction:
-Phyllodes tumor with minimal deviation adenocarcinoma is an exceptionally rare malignant phyllodes tumor where the stromal component contains minimal deviation adenocarcinoma (adenoma malignum), characterized by well-differentiated glandular structures that closely mimic benign glands.
Origin:
-Develops from intralobular breast stroma with differentiation toward minimal deviation adenocarcinoma
-May arise through subtle malignant transformation of stromal cells with preservation of glandular architecture.
Classification:
-WHO Classification categorizes this as malignant phyllodes tumor with heterologous elements
-Minimal deviation adenocarcinoma component shows deceptively benign-appearing glandular structures.
Epidemiology:
-Exceptionally rare with fewer than 3 cases reported worldwide
-Peak age 40-60 years
-Female predominance
-Clinical behavior difficult to predict due to well-differentiated appearance.

Clinical Features

Presentation:
-Large, slowly growing breast mass
-Usually presents as painless mass
-May show very gradual enlargement over years
-Often clinically benign appearance.
Symptoms:
-Progressive but slow breast enlargement
-Breast asymmetry
-Usually completely asymptomatic
-May be discovered incidentally
-Nipple discharge rare.
Risk Factors:
-Previous phyllodes tumor history
-Peutz-Jeghers syndrome possible association
-STK11/LKB1 mutations
-Family history of adenoma malignum.
Screening:
-No specific screening available
-Clinical examination may not detect malignancy
-Imaging may appear benign
-Tissue diagnosis essential but challenging.

Master Phyllodes Tumor with Minimal Deviation Adenocarcinoma Pathology with RxDx

Access 100+ pathology videos and expert guidance with the RxDx app

Gross Description

Appearance:
-Large, well-circumscribed mass with deceptively benign appearance
-Cut surface shows gray-white areas with small cystic spaces
-Soft to firm consistency.
Characteristics:
-Size typically >3 cm (range 2-10 cm)
-Soft consistency
-Deceptively benign gross appearance
-Multiple small cystic spaces
-No obvious necrosis.
Size Location:
-Can occur in any breast region
-Usually involves moderate breast tissue
-Unilateral presentation
-Well-circumscribed borders.
Multifocality:
-Typically unifocal mass
-Multiple glandular areas within tumor
-Complex but subtle architecture
-Local extension very rare.

Microscopic Description

Histological Features:
-Biphasic tumor with epithelial and mesenchymal components
-Minimal deviation adenocarcinoma areas show well-differentiated glandular structures that closely mimic normal or benign glands.
Cellular Characteristics:
-Well-differentiated epithelial cells with minimal atypia
-Bland nuclear features
-Very low mitotic activity
-Abundant mucin production
-Pseudostratification absent.
Architectural Patterns:
-Complex branching glandular structures
-Irregular glandular shapes and sizes
-Back-to-back glands
-Stromal invasion subtle
-Desmoplastic reaction minimal.
Grading Criteria:
-Well-differentiated adenocarcinoma
-Minimal nuclear atypia
-Very low mitotic rate (<2 per 10 HPF)
-Architectural complexity main malignant feature.

Immunohistochemistry

Positive Markers:
-Cytokeratins positive (CK7 strong, CK20 variable)
-EMA positive
-CEA positive
-CA 19-9 positive
-Mucin stains strongly positive
-Epithelial component: CK7+, EMA+.
Negative Markers:
-TTF-1 negative
-CDX2 variable
-PAX8 negative
-WT1 negative
-p16 usually negative.
Diagnostic Utility:
-Strong mucin production characteristic
-CEA and CA 19-9 positivity supportive
-Cytokeratin profile helps confirm epithelial nature.
Molecular Subtypes:
-STK11/LKB1-associated type
-Sporadic type
-KRAS-mutated type
-HIK1083-positive type.

Molecular/Genetic

Genetic Mutations:
-STK11/LKB1 mutations (in Peutz-Jeghers syndrome)
-KRAS mutations common
-GNAS mutations possible
-PIK3CA alterations.
Molecular Markers:
-HIK1083 antibody positive (specific marker)
-Low Ki-67 proliferation index
-High mucin gene expression
-STK11 loss in associated cases.
Prognostic Significance:
-STK11 mutations associated with Peutz-Jeghers syndrome
-KRAS mutations may predict aggressive behavior
-Size and invasion depth important.
Therapeutic Targets:
-mTOR pathway inhibitors
-MEK inhibitors for KRAS-mutated tumors
-Mucin-targeted therapies under development.

Differential Diagnosis

Similar Entities:
-Benign breast glands
-Complex sclerosing lesion
-Atypical ductal hyperplasia
-Metastatic minimal deviation adenocarcinoma from cervix
-Mucinous carcinoma.
Distinguishing Features:
-Phyllodes with minimal deviation: Leaf-like areas, HIK1083+
-Benign glands: Regular architecture
-Metastatic: Clinical history, HPV status.
Diagnostic Challenges:
-Recognition of subtle malignant features
-Distinction from benign glandular proliferation
-Assessment of invasion
-HIK1083 staining helpful.
Rare Variants:
-Minimal deviation adenocarcinoma with mucinous features
-Mixed minimal deviation and conventional adenocarcinoma
-Cystic variant.

Sample Pathology Report

Template Format

Sample Pathology Report

Complete Report: This is an example of how the final pathology report should be structured for this condition.

Specimen Information

[specimen type], measuring [size] cm in greatest dimension

Diagnosis

[diagnosis name]

Classification

Classification: [classification system] [grade/type]

Histological Features

Shows [architectural pattern] with [nuclear features] and [mitotic activity]

Size and Extent

Size: [X] cm, extent: [local/regional/metastatic]

Margins

Margins are [involved/uninvolved] with closest margin [X] mm

Lymphovascular Invasion

Lymphovascular invasion: [present/absent]

Lymph Node Status

Lymph nodes: [X] positive out of [X] examined

Special Studies

IHC: [marker]: [result]

Molecular: [test]: [result]

[other study]: [result]

Prognostic Factors

Prognostic factors: [list factors]

Final Diagnosis

Final diagnosis: [complete diagnosis]